Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis’ Cosentyx Wins Two New Approvals | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Novartis’ Cosentyx Wins Two New Approvals

Gains new indications for active ankylosing spondylitis and active psoriatic arthritis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis’ Cosentyx (secukinumab) has been approved by the FDA for two new indications, active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). Both are life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine.  

Cosentyx is now the first and only interleukin-17A (IL-17A) antagonist approved for AS, as well as moderate to severe plaque psoriasis and PsA, which impacts as many as 30% of patients with psoriasis. Cosentyx was approved for moderate to severe plaque psoriasis in January 2015.

The approvals are based on two AS and two PsA placebo-controlled Phase III studies in more than 1,500 adult patients with either AS or PsA. Cosentyx met the primary endpoints achieving statistically significant improvements versus placebo in the signs and symptoms of AS and PsA, as measured by at least a 20% improvement in the Assessment of Spondyloarthritis International Society criteria (ASAS20) and a 20% reduction in the American College of Rheumatology (ACR20) response criteria.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics